PE20070493A1 - Compuestos derivados de 2-azetidinonas como inhibidores de la absorcion de colesterol - Google Patents
Compuestos derivados de 2-azetidinonas como inhibidores de la absorcion de colesterolInfo
- Publication number
- PE20070493A1 PE20070493A1 PE2006001201A PE2006001201A PE20070493A1 PE 20070493 A1 PE20070493 A1 PE 20070493A1 PE 2006001201 A PE2006001201 A PE 2006001201A PE 2006001201 A PE2006001201 A PE 2006001201A PE 20070493 A1 PE20070493 A1 PE 20070493A1
- Authority
- PE
- Peru
- Prior art keywords
- alkyl
- phenyl
- aryl
- inhibitors
- substituted
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
- C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
- C07D205/06—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D205/08—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with one oxygen atom directly attached in position 2, e.g. beta-lactams
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/10—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing aromatic rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Diabetes (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
SE REFIERE A COMPUESTOS 2-AZETIDINONAS SUSTITUIDAS DE FORMULA (I) DONDE Ar1 ES ARILO OPCIONALMENTE SUSTITUIDO CON R4 DONDE R4 ES OR5, O(CO)R5, COR5, ENTRE OTROS; X, Y Y Z SON CH2, CH(ALQUILO(C1-C6)) O C(ALQUILO(C1-C6))2; R ES OR6, O(CO)R6, UN RESTO AZUCAR, ENTRE OTROS; R1 ES H, ALQUILO(C1-C6), ARILO O R Y R1 JUNTOS SON OXO; R2 ES OR6, O(CO)R6, ENTRE OTROS, DONDE R5 Y R6 SON H, ALQUILO(C1-C6), ARILO O ALQUILO(C1-C6)ARIL SUSTITUIDO; R3 ES H, ALQUILO(C1-C6), ARILO O R2 Y R3 JUNTOS SON OXO; q Y r SON 0 O 1; m, n Y p SON DE 0 A 4; R9 ES -C=C-(CH2)y-NR10R11, -C=C-(CH2)y-NR10R11 O -(CH2)w-NR10R11, DONDE w ES DE 1 A 8; y ES DE 1 A 6; R10 ES H O ALQUILO(C1-C3); R11 ES H, ALQUILO(C1-C3), -C(O)-ALQUILO(C1-C3), ENTRE OTROS; R12 ES ALQUILO(C1-C15) SUSTITUIDO CON OH, ENTRE OTROS; R13 ES H U OH. SON COMPUESTOS PREFERIDOS: N-[3-(4-{(2S,3R)-2-{4-[3,4-DIHIDROXI-3-(HIDROXIMETIL)BUTIL]FENIL}-3-[(3S)-3-(4-FLUOROFENIL)-3-HIDROXIPROPIL]-4-OXOAZETIDIN-1-IL}FENIL)PROPIL]METANOSULFONAMIDA, N-[3-(4-{(2S,3R)-3-[(3S)-3-(4-FLUOROFENIL)-3-HIDROXIPROPIL]-2-[4-(6-HIDROXIHEXIL)FENIL]-4-OXOAZETIDIN-1-IL}FENIL)PROPIL]-N-METILMETANOSULFONAMIDA, N-[3-(4-{(2S,3R)-2-{4-[3,4-DIHIDROXI-3-(HIDROXIMETIL)BUTIL]-2-HIDROXIFENIL}-3-[(3S)-3-(4-FLUOROFENIL)-3-HIDROXIPROPIL]-4-OXOAZETIDIN-1-IL}FENIL)PROPIL]METANOSULFONAMIDA, ENTRE OTROS. SE REFIERE TAMBIEN A UNA COMPOSICION FARMACEUTICA. DICHOS COMPUESTOS SON INHIBIDORES DE LA ABSORCION DE COLESTEROL SIENDO UTILES EN EL TRATAMIENTO DE HIPERCOLESTEROLEMIA
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US72378105P | 2005-10-05 | 2005-10-05 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20070493A1 true PE20070493A1 (es) | 2007-06-13 |
Family
ID=37845278
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2006001201A PE20070493A1 (es) | 2005-10-05 | 2006-10-03 | Compuestos derivados de 2-azetidinonas como inhibidores de la absorcion de colesterol |
Country Status (25)
| Country | Link |
|---|---|
| US (2) | US20090137546A1 (es) |
| EP (1) | EP1934175B1 (es) |
| JP (1) | JP4879991B2 (es) |
| KR (1) | KR20080050610A (es) |
| CN (1) | CN101277930A (es) |
| AR (1) | AR058068A1 (es) |
| AT (1) | ATE488495T1 (es) |
| AU (1) | AU2006302584B2 (es) |
| BR (1) | BRPI0616834A2 (es) |
| CA (1) | CA2624481C (es) |
| CR (1) | CR9903A (es) |
| DE (1) | DE602006018341D1 (es) |
| DO (1) | DOP2006000211A (es) |
| EA (1) | EA200801008A1 (es) |
| ES (1) | ES2354460T3 (es) |
| GT (1) | GT200600444A (es) |
| IL (1) | IL190434A0 (es) |
| MA (1) | MA30006B1 (es) |
| NO (1) | NO20082075L (es) |
| PE (1) | PE20070493A1 (es) |
| SV (1) | SV2009002863A (es) |
| TN (1) | TNSN08153A1 (es) |
| TW (1) | TW200806623A (es) |
| WO (1) | WO2007044318A2 (es) |
| ZA (1) | ZA200802587B (es) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7176193B2 (en) * | 2002-06-19 | 2007-02-13 | Sanofi-Aventis Deutschland Gmbh | Acid-group-substituted diphenylazetidinones, process for their preparation, medicaments comprising these compounds, and their use |
| GB0215579D0 (en) * | 2002-07-05 | 2002-08-14 | Astrazeneca Ab | Chemical compounds |
| JP4688819B2 (ja) * | 2003-12-23 | 2011-05-25 | アストラゼネカ アクチボラグ | コレステロール吸収阻害活性を有するジフェニルアゼチジノン誘導体 |
| CN100471835C (zh) * | 2003-12-23 | 2009-03-25 | 默克公司 | 抗高胆固醇血症化合物 |
| GB0329778D0 (en) * | 2003-12-23 | 2004-01-28 | Astrazeneca Ab | Chemical compounds |
| UY29607A1 (es) * | 2005-06-20 | 2007-01-31 | Astrazeneca Ab | Compuestos quimicos |
| AR057380A1 (es) * | 2005-06-22 | 2007-11-28 | Astrazeneca Ab | Compuestos quimicos derivados de 2-azetidinona y uso terapeutico de los mismos |
| MY148538A (en) * | 2005-06-22 | 2013-04-30 | Astrazeneca Ab | Novel 2-azetidinone derivatives as cholesterol absorption inhibitors for the treatment of hyperlipidaemic conditions |
| AR057383A1 (es) * | 2005-06-22 | 2007-12-05 | Astrazeneca Ab | Compuestos quimicos derivados de 2-azetidinona, formulacion farmaceutica y un proceso de preparacion del compuesto |
| SA06270191B1 (ar) * | 2005-06-22 | 2010-03-29 | استرازينيكا ايه بي | مشتقات من 2- أزيتيدينون جديدة باعتبارها مثبطات لامتصاص الكوليسترول لعلاج حالات فرط نسبة الدهون في الدم |
| AR054482A1 (es) * | 2005-06-22 | 2007-06-27 | Astrazeneca Ab | Derivados de azetidinona para el tratamiento de hiperlipidemias |
| TW200806623A (en) * | 2005-10-05 | 2008-02-01 | Merck & Co Inc | Anti-hypercholesterolemic compounds |
| DE102005055726A1 (de) * | 2005-11-23 | 2007-08-30 | Sanofi-Aventis Deutschland Gmbh | Hydroxy-substituierte Diphenylazetidinone, Verfahren zu deren Herstellung, diese Verbindungen enthaltende Arzneimittel und deren Verwendung |
| TW200811098A (en) * | 2006-04-27 | 2008-03-01 | Astrazeneca Ab | Chemical compounds |
| AU2007342603A1 (en) * | 2006-12-20 | 2008-07-17 | Merck Sharp & Dohme Corp. | Anti-hypercholesterolemic compounds |
| DE102009023046B4 (de) | 2008-05-30 | 2016-10-13 | Hyundai Motor Company | Automatisch schaltbares Getriebe eines Kraftfahrzeuges |
| WO2010056788A1 (en) * | 2008-11-17 | 2010-05-20 | Merck Sharp & Dohme Corp. | Anti-hypercholesterolemic compounds |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0596015B1 (en) * | 1991-07-23 | 1997-10-01 | Schering Corporation | Substituted beta-lactam compounds useful as hypocholesterolemic agents and processes for the preparation thereof |
| US5631365A (en) * | 1993-09-21 | 1997-05-20 | Schering Corporation | Hydroxy-substituted azetidinone compounds useful as hypocholesterolemic agents |
| CA2191455A1 (en) * | 1994-06-20 | 1995-12-28 | Wayne Vaccaro | Substituted azetidinone compounds useful as hypocholesterolemic agents |
| US5624920A (en) * | 1994-11-18 | 1997-04-29 | Schering Corporation | Sulfur-substituted azetidinone compounds useful as hypocholesterolemic agents |
| NZ526593A (en) * | 2000-12-21 | 2005-02-25 | Aventis Pharma Gmbh | Novel 1,2-diphenzylazetidinones, method for producing the same, medicaments containing said compounds, and the use thereof for treating disorders of the lipid metabolism |
| TWI291957B (en) * | 2001-02-23 | 2008-01-01 | Kotobuki Pharmaceutical Co Ltd | Beta-lactam compounds, process for repoducing the same and serum cholesterol-lowering agents containing the same |
| US7176193B2 (en) * | 2002-06-19 | 2007-02-13 | Sanofi-Aventis Deutschland Gmbh | Acid-group-substituted diphenylazetidinones, process for their preparation, medicaments comprising these compounds, and their use |
| US7176194B2 (en) * | 2002-06-19 | 2007-02-13 | Sanofi-Aventis Deutschland Gmbh | Ring-substituted diphenylazetidinones, process for their preparation, medicaments comprising these compounds, and their use |
| CA2517571C (en) * | 2003-03-07 | 2011-07-05 | Schering Corporation | Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof |
| JP2005015434A (ja) * | 2003-06-27 | 2005-01-20 | Kotobuki Seiyaku Kk | 血清コレステロール低下剤或はアテローム性硬化症の予防又は治療剤 |
| CN100471835C (zh) * | 2003-12-23 | 2009-03-25 | 默克公司 | 抗高胆固醇血症化合物 |
| WO2006086562A2 (en) * | 2005-02-09 | 2006-08-17 | Microbia, Inc. | Phenylazetidinone derivatives |
| CA2611142A1 (en) * | 2005-06-15 | 2006-12-28 | Merck & Co., Inc. | Anti-hypercholesterolemic compounds |
| TW200806623A (en) * | 2005-10-05 | 2008-02-01 | Merck & Co Inc | Anti-hypercholesterolemic compounds |
| DE102005055726A1 (de) * | 2005-11-23 | 2007-08-30 | Sanofi-Aventis Deutschland Gmbh | Hydroxy-substituierte Diphenylazetidinone, Verfahren zu deren Herstellung, diese Verbindungen enthaltende Arzneimittel und deren Verwendung |
| EP2091915A1 (de) * | 2006-11-02 | 2009-08-26 | Sanofi-Aventis Deutschland GmbH | Neues mit piperazin-1-sulfonsäure substituiertes diphenylazetidinon mit verbesserten pharmakologischen eigenschaften |
-
2006
- 2006-09-26 TW TW095135631A patent/TW200806623A/zh unknown
- 2006-09-27 AR ARP060104231A patent/AR058068A1/es unknown
- 2006-09-29 US US11/992,990 patent/US20090137546A1/en not_active Abandoned
- 2006-09-29 CN CNA2006800369359A patent/CN101277930A/zh active Pending
- 2006-09-29 CA CA2624481A patent/CA2624481C/en not_active Expired - Fee Related
- 2006-09-29 EP EP06816084A patent/EP1934175B1/en active Active
- 2006-09-29 BR BRPI0616834A patent/BRPI0616834A2/pt not_active IP Right Cessation
- 2006-09-29 DE DE602006018341T patent/DE602006018341D1/de active Active
- 2006-09-29 AU AU2006302584A patent/AU2006302584B2/en not_active Ceased
- 2006-09-29 ES ES06816084T patent/ES2354460T3/es active Active
- 2006-09-29 EA EA200801008A patent/EA200801008A1/ru unknown
- 2006-09-29 KR KR1020087008305A patent/KR20080050610A/ko not_active Withdrawn
- 2006-09-29 WO PCT/US2006/038551 patent/WO2007044318A2/en not_active Ceased
- 2006-09-29 AT AT06816084T patent/ATE488495T1/de not_active IP Right Cessation
- 2006-09-29 JP JP2008534613A patent/JP4879991B2/ja not_active Expired - Fee Related
- 2006-10-03 GT GT200600444A patent/GT200600444A/es unknown
- 2006-10-03 PE PE2006001201A patent/PE20070493A1/es not_active Application Discontinuation
- 2006-10-04 US US11/542,966 patent/US7704988B2/en not_active Expired - Fee Related
- 2006-10-05 DO DO2006000211A patent/DOP2006000211A/es unknown
-
2008
- 2008-03-20 ZA ZA200802587A patent/ZA200802587B/xx unknown
- 2008-03-25 IL IL190434A patent/IL190434A0/en unknown
- 2008-04-04 TN TNP2008000153A patent/TNSN08153A1/en unknown
- 2008-04-04 SV SV2008002863A patent/SV2009002863A/es not_active Application Discontinuation
- 2008-04-18 CR CR9903A patent/CR9903A/es not_active Application Discontinuation
- 2008-05-02 MA MA30894A patent/MA30006B1/fr unknown
- 2008-05-02 NO NO20082075A patent/NO20082075L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| MA30006B1 (fr) | 2008-12-01 |
| EP1934175A2 (en) | 2008-06-25 |
| NO20082075L (no) | 2008-07-04 |
| WO2007044318A3 (en) | 2007-07-12 |
| US20090137546A1 (en) | 2009-05-28 |
| JP4879991B2 (ja) | 2012-02-22 |
| SV2009002863A (es) | 2009-02-19 |
| GT200600444A (es) | 2007-05-04 |
| TNSN08153A1 (en) | 2009-10-30 |
| US7704988B2 (en) | 2010-04-27 |
| IL190434A0 (en) | 2008-11-03 |
| JP2009511475A (ja) | 2009-03-19 |
| ZA200802587B (en) | 2009-06-24 |
| US20070078098A1 (en) | 2007-04-05 |
| ATE488495T1 (de) | 2010-12-15 |
| WO2007044318A2 (en) | 2007-04-19 |
| ES2354460T3 (es) | 2011-03-15 |
| BRPI0616834A2 (pt) | 2016-08-23 |
| CR9903A (es) | 2008-07-29 |
| AU2006302584A1 (en) | 2007-04-19 |
| TW200806623A (en) | 2008-02-01 |
| CA2624481A1 (en) | 2007-04-19 |
| EP1934175B1 (en) | 2010-11-17 |
| DE602006018341D1 (de) | 2010-12-30 |
| CN101277930A (zh) | 2008-10-01 |
| CA2624481C (en) | 2012-04-03 |
| AU2006302584B2 (en) | 2011-10-13 |
| DOP2006000211A (es) | 2007-05-31 |
| AR058068A1 (es) | 2008-01-23 |
| KR20080050610A (ko) | 2008-06-09 |
| EA200801008A1 (ru) | 2009-02-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20070493A1 (es) | Compuestos derivados de 2-azetidinonas como inhibidores de la absorcion de colesterol | |
| PE20051170A1 (es) | DERIVADOS DE PIRROL COMO INHIBIDORES DEL FACTOR Xa | |
| AR058754A1 (es) | Procesos para preparar compuestos intermediarios utiles para la preparacion de ezetimibe | |
| PE20091400A1 (es) | Derivados de n-(2-amino-fenil)-amida como inhibidores de hdac | |
| PE20110598A1 (es) | Inhibidores de las enzimas de proteina cinasa activadas por mitogeno p38 | |
| ECSP066414A (es) | Derivados de malonamida que bloquean la actividad de gama-secretasa | |
| AR074306A1 (es) | Aminotetrahidropiranos como inhibidores de dipeptidil peptidasa-iv para el tratamiento o prevencion de diabetes | |
| RU2409562C2 (ru) | Новые производные 2-азетидинона в качестве ингибиторов всасывания холестерина для лечения гиперлипидемических состояний | |
| CY1108445T1 (el) | Νεα μεθοδος συνθεσης και νεα κρυσταλλικη μορφη της αγομελατινης καθως και φαρμακευτικες συνθεσεις που την περιεχουν | |
| DK1373230T3 (da) | Enantiselektiv syntese af azetidinon mellemprodukter | |
| NO20065830L (no) | Substituerte 2-kinolyloksazoler som er anvendbare som PDE4-inhibitorer. | |
| PE20091816A1 (es) | Inhibidores de bace | |
| RU2409572C2 (ru) | Новые производные 2-азетидинона в качестве ингибиторов всасывания холестерина для лечения гиперлипидемических состояний | |
| PE20081354A1 (es) | Compuestos de azaindolilo como inhibidores de mek | |
| PE20142185A1 (es) | Pirrolidina-2-carboxamidas sustituidas | |
| PE20081532A1 (es) | Compuestos novedosos | |
| NO20074763L (no) | (1,5-difenyl-1H-pyrazol-3-yl)oksadiazolderivater, fremgangsmate ved fremstilling derav og anvendelse av samme i terapi | |
| PE20080951A1 (es) | DERIVADOS DE 2-OXO-ETIL-AMINO-PROPIONAMIDA-PIRROLIDIN-2-IL-SUSTITUIDOS COMO INHIBIDORES DEL ENLACE DE LA PROTEINA Smac AL INHIBIDOR DE LA PROTEINA DE APOPTOSIS | |
| PE20091258A1 (es) | Derivados de piridina como activadores de la guanilato ciclasa soluble | |
| AR071617A1 (es) | Bencenosulfonamidas de oxazol y tiazol, composiciones farmaceuticas que las contienen, proceso de preparacion y uso de las mismas como agentes anticancerigenos. | |
| PE20040864A1 (es) | Derivados de heterobiarilo como inhibidores de metaloproteinasa de la matriz | |
| WO2007030721A3 (en) | Processes for the preparation of (3r,4s)-4-((4-benzyloxy)phenyl)-1-(4-fluorophenyl)-3-((s)-3-(4-fluorophenyl)-3-hydroxypropyl)-2-azetidinone, an intermediate for the synthesis of ezetimibe | |
| PE20080856A1 (es) | Inhibidores de metaloproteasas de matriz | |
| PE20020718A1 (es) | 2-azetidinonas sustituidas con azucares utiles como agentes hipocolesterolemicos | |
| PE20060150A1 (es) | Antagonistas de cgrp seleccionados, composiciones farmaceuticas y procedimiento para su preparacion |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC | Refusal |